Vaccibody receives grant to develop VB10.16

Vaccibody has received a EUR 2 million grant from the Norwegian Research Council's BIA programme to develop a novel therapeutic vaccine against precancerous lesions of the cervix. The new vaccine, VB10.16, will be based on the company's Vaccibody DNA vaccine platform, which targets antigen-presenting cells. Combined with previous funding of EUR 875,000, this new grant will enable the company to take VB10.16 through to clinical trials in early 2014.

This article is tagged to:
Sector: Medical Devices
Geography: Norway

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.